Product Description
Progen was developing cgc-11047, an intravenous DNA synthesis inhibitor, for the treatment of CNV from Age Related Macular Degeneration (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00446654)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Progen
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Prostate Cancer
Phase 1: Lymphoma|Macular Degeneration
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT00705874 | P1 |
Completed |
Lymphoma |
2011-08-01 |
|
HSC2006-0099 | P2 |
Terminated |
Prostate Cancer |
2007-11-01 |
|
47-MD-002 | P1 |
Completed |
Macular Degeneration |
2007-10-01 |